Advertisement
Advertisement
U.S. markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Protagonist Therapeutics, Inc. (PTGX)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
8.43+0.18 (+2.18%)
At close: 04:00PM EDT
8.43 0.00 (0.00%)
After hours: 05:00PM EDT
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Price Crosses Moving Average

Price Crosses Moving Average

Previous Close8.25
Open8.36
Bid7.50 x 800
Ask8.44 x 800
Day's Range8.28 - 8.78
52 Week Range6.91 - 38.11
Volume508,285
Avg. Volume957,457
Market Cap413.779M
Beta (5Y Monthly)2.55
PE Ratio (TTM)N/A
EPS (TTM)-2.58
Earnings DateNov 01, 2022 - Nov 07, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est36.00
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for PTGX

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Protagonist Therapeutics, Inc.
    Analyst Report: Bristol-Myers Squibb CompanyBristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
    Rating
    Fair Value
    Economic Moat
    13 days agoMorningstar
View more
  • Zacks

    Protagonist Therapeutics (PTGX) Upgraded to Buy: What Does It Mean for the Stock?

    Protagonist Therapeutics (PTGX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

  • PR Newswire

    Protagonist Therapeutics Reports Granting of Inducement Award

    Protagonist Therapeutics, Inc. (Nasdaq:PTGX) today reported that on September 15, 2022, it issued an inducement award to Pedro Oyuela, M.D., the Company's recently hired Vice President of Pharmacovigilance, in accordance with the terms of Dr. Oyuela's employment offer letter. The award was granted under the Protagonist Therapeutics Amended and Restated Inducement Plan, which was adopted May 29, 2018, and amended February 18, 2020 and February 15, 2022.

  • Zacks

    How Much Upside is Left in Protagonist Therapeutics (PTGX)? Wall Street Analysts Think 302%

    The consensus price target hints at a 301.5% upside potential for Protagonist Therapeutics (PTGX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Advertisement
Advertisement